Dealmaking across oncology and radiopharmaceuticals accelerated this week, with licensing agreements reshaping antibody-drug conjugate and breast cancer pipelines, alongside a multibillion-dollar merger in nuclear medicine. This collaboration reflects our shared commitment to bringing differentiated therapies to patients," said Iker Huerga, chief executive officer of Pathos AI. Pathos AI and AstraZeneca advance AZD4241Along with its licensing agreement with Alphamab, Pathos AI also announced a collaboration and co-exclusive licensing agreement with AstraZeneca, aiming to advance AZD4241, a preclinical investigational therapy for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.2 As part of the deal, Pathos will assume responsibility for the asset's early clinical development. Patients are waiting," said Iker Huerga, chief executive officer of Pathos AI. "Lantheus is the ideal partner to accelerate what we have been building at Curium.